Praxis Precision Medicines (PRAX) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 10, 2026, with voting on director elections, auditor ratification, and executive compensation approval.

• 2025 saw significant clinical, regulatory, and financial milestones, including positive pivotal trial results, FDA breakthrough designations, and a 283% increase in stock price.

• The company’s pipeline advanced with multiple late-stage programs and a successful $567.1 million public offering.

Voting matters and shareholder proposals

• Shareholders will vote to elect three Class III directors for terms expiring in 2029.

• Ratification of Ernst & Young LLP as independent auditor for 2026 is on the agenda.

• Advisory (non-binding) vote on executive compensation (say-on-pay) is included.

• Procedures for shareholder proposals and director nominations for future meetings are outlined.

Board of directors and corporate governance

• The board consists of nine members divided into three staggered classes, with a majority deemed independent under Nasdaq rules.

• Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.

• Board leadership is separated between the CEO and Chairman roles.

• Directors are encouraged to attend meetings, and a stock ownership policy for non-employee directors was adopted.